Eli Lilly and Company (NYSE:LLY) Trading 1.9% Higher

Eli Lilly and Company (NYSE:LLY) traded up 1.9% on Tuesday . The company traded as high as $882.90 and last traded at $882.52. 579,224 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 2,953,739 shares. The stock had previously closed at $865.97.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Berenberg Bank upped their target price on shares of Eli Lilly and Company from $850.00 to $1,000.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Bank of America reissued a “buy” rating and issued a $1,000.00 target price on shares of Eli Lilly and Company in a research note on Monday, June 24th. BMO Capital Markets reissued an “outperform” rating and issued a $1,001.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, July 3rd. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,023.00 price objective on shares of Eli Lilly and Company in a research note on Friday, July 5th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $858.72.

Eli Lilly and Company Trading Down 4.5 %

The stock’s 50 day simple moving average is $868.41 and its two-hundred day simple moving average is $780.32. The stock has a market capitalization of $780.47 billion, a PE ratio of 120.69, a PEG ratio of 1.91 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the business earned $1.62 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, sell-side analysts expect that Eli Lilly and Company will post 13.78 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of Eli Lilly and Company stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,214,704 shares of company stock worth $1,066,841,316. Corporate insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

A number of large investors have recently modified their holdings of the company. Independent Advisor Alliance boosted its stake in shares of Eli Lilly and Company by 1.7% in the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock valued at $18,810,000 after purchasing an additional 544 shares in the last quarter. Apexium Financial LP boosted its position in Eli Lilly and Company by 1,819.1% during the fourth quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock valued at $6,667,000 after buying an additional 10,842 shares during the period. Clear Harbor Asset Management LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $363,000. Terril Brothers Inc. grew its stake in shares of Eli Lilly and Company by 113.2% during the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after buying an additional 429 shares during the last quarter. Finally, Capital Planning LLC purchased a new position in shares of Eli Lilly and Company in the first quarter worth about $262,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.